Cutera Introduces Pioneering Residency Program for Dermatology
A New Initiative to Enhance Clinical Education and Innovation
CUTERA, INC., a notable provider of aesthetic and dermatological solutions, has launched an exceptional residency program aimed at integrating cutting-edge technology into dermatology training. This innovative program will enhance access to AviClear, the first FDA-cleared 1726 nm laser specifically designed for the long-term treatment of acne, within residency programs across North America.
The program focuses on supporting advancements in acne care, research, and education, by embedding AviClear into the curriculum of notable academic institutions. This approach equips future dermatologists with essential tools and technology, allowing them to expand their expertise and improve patient outcomes.
According to Taylor Harris, CEO of Cutera Inc., "Our mission is to empower the next generation of dermatologists through education and innovation. By incorporating AviClear into residency programs, we are enhancing clinical training while reaffirming our dedication to pioneering solutions that positively impact dermatology and the lives we touch."
Designed as a 24-month partnership, the program includes technology integration and structured clinical training alongside valuable collaboration opportunities. These include co-authoring publications, conducting research, giving podium presentations, and exploring new clinical applications. Participants will also be exposed to Cutera's broader technology portfolio, thereby gaining insights into a variety of innovations in dermatology and aesthetics.
"Residents can now access advanced technology like AviClear early in their training, giving them practical experience in the evolving landscape of acne care," remarked Ashish C. Bhatia, M.D., FAAD, Co-Director of Dermatologic, Laser and Cosmetic Surgery at Oak Dermatology. "Additionally, this partnership opens up exciting new avenues for research into conditions affecting the sebaceous glands, like sebaceous hyperplasia and hidradenitis suppurativa, pushing the boundaries of what is achievable in dermatologic treatment."
Since AviClear's introduction, countless treatments have successfully been performed globally, offering practitioners robust evidence of its effectiveness, safety, and long-lasting results. Beyond acne treatment, Cutera's dedicated clinical research team is investigating AviClear for various new applications related to the sebaceous glands, including sebaceous hyperplasia and hidradenitis suppurativa, along with ongoing exploratory studies. These ongoing efforts underscore the dynamic capacity of the 1726 nm wavelength and Cutera's ongoing commitment to driving innovation through rigorous research.
Cutera is actively inviting applications from universities and training programs that wish to be part of this cutting-edge Residency Program. Interested entities can learn more and submit their applications via email.
About Cutera, Inc.
Cutera has established itself as a prominent provider of aesthetic and dermatological solutions worldwide. Over the last 25 years, the company has been focused on enhancing lives through science-backed medical aesthetic technologies and fostering strong partnerships in healthcare.
Safety Information for AviClear:
Indications for Use: AviClear is FDA-cleared for effectively treating mild to severe inflammatory acne vulgaris.
Contraindications: This treatment should not be administered to pregnant individuals or those undergoing skin cancer therapy.
Potential Side Effects: Treatment-related side effects may include discomfort, erythema and edema, temporary acne flare-ups, skin dryness, blisters, scabbing, hyperpigmentation, and changes in skin texture, among others.
Warnings: AviClear should not be applied over dysplastic nevi, questionable pigmented lesions, or tattoos.
The AviClear Laser System has not been clinically examined on lips, eyelids, or eyebrows. Only the topical anesthetics recommended by Cutera are to be used for AviClear treatments.
Frequently Asked Questions
What is the Cutera Residency Program?
The Cutera Residency Program is a new initiative designed to integrate AviClear into dermatology training, equipping future dermatologists with essential technology and tools.
Who can apply for the residency program?
Universities and dermatology residency programs interested in incorporating AviClear into their training can apply to participate in the Cutera Residency Program.
What technology does the program focus on?
The program specifically focuses on AviClear, a cutting-edge 1726 nm laser that is FDA-cleared for treating various forms of acne.
What opportunities does the program offer participants?
Participants can collaborate on research, publications, presentations, and gain access to a wide spectrum of innovations in dermatology and aesthetics through Cutera.
How has AviClear been received in clinical settings?
AviClear has been widely utilized globally, with extensive clinical evidence supporting its safety, efficacy, and long-term benefits in acne treatment.
